• Technology

    Technology

    Vector, target, indication getting the new combination to the clinics
  • About us

    About us

    Developing a single dose treatment for rheumatoid arthritis
  • Technology

    Technology

    Single dose treatment for chronic diseases
  • Technology

    Technology

    Vector, target, indication getting the new combination to the clinics
  • About us

    About us

    Developing a single dose treatment for rheumatoid arthritis
  • Clinical program

    Clinical program

    10 years of development getting ready for clinical trial
  • Technology

    Technology

    Single dose treatment for chronic diseases
  • HOME 767 310 02
  • HOME 767 310 01

About us

Arthrogen B.V., a subsidiary of MeiraGTx B.V., is an Amsterdam based biopharmaceutical company developing local gene therapy for different indications, using viral mediated gene transfer.

Technology

The therapeutic vectors are derived from natural occurring adeno-associated viruses (AAV) that are not pathogenic in humans.

Arthrogen is now part of MeiraGTx

Select CONTINUE to continue to Arthrogen

Select MEIRAGTX to learn more about MeiraGTx